Fiche centre
Alfred Health
Melbourne — Australia
Essais liés7clinical trials
VilleMelbournelocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06612775
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Carisbamate | Épilepsie | Phase 3 | NCT05219617 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | RECRUITING |
| Test drug CB03-154 5mg group | Épilepsie | Phase 2 | NCT06612775 | A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | RECRUITING |
| Domvanalimab | Cancer | Phase 2 | NCT06727565 | VELOCITY-HNSCC — Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | ACTIVE_NOT_RECRUITING |
| Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters | Épilepsie | Non applicable | NCT06143293 | RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS | ACTIVE_NOT_RECRUITING |
| SRP-1001 for Injection | Myopathies | Phase 1/2 | NCT06131983 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 | ENROLLING_BY_INVITATION |
| SRP-1003 IV Infusion | Myopathies | Phase 1/2 | NCT06138743 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | ENROLLING_BY_INVITATION |
| CNM-Au8 | SEP | Phase 2 | NCT03536559 | VISIONARY-MS — Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis | TERMINATED |